NFKB1 and neoplasm: The same group demonstrated that bortezomib arrested tumor growth by blocking Sp1/NF-κB/Histone deacetylase (HDAC) complex, upregulating miR-29b downregulating c-KIT gene and, finally, inibiting aberrant TK activity both in vitro and in vivo [117,118].